Corvus Pharmaceuticals to Present at 2026 Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 /CourierPR/ -- Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company, will participate in the 2026 Cantor Global Healthcare Conference, held in New York City. The firm's leadership team will engage in one-on-one meetings with investors and present at a fireside chat session on September 10, 2026, at 1:00 PM Eastern Time (10:00 AM Pacific Time).

During the fireside chat, Corvus will share updates on its lead product candidate, soquelitinib, an investigational, oral, small molecule drug that selectively inhibits interleukin-2 receptor common γ-chain (ITK). Soquelitinib is currently in a registration Phase 3 clinical trial for relapsed or refractory peripheral T-cell lymphoma (PTCL) and is also being evaluated in a Phase 2 trial for atopic dermatitis. The company's other clinical-stage candidates are advancing in various cancer treatments.

Corvus Pharmaceuticals is dedicated to developing ITK inhibition as a novel approach to immunotherapy for a range of immune diseases and cancers. The company's commitment to innovation and patient care is exemplified by its ongoing clinical trials and strategic partnerships within the healthcare industry.